In The Medicines Co. v. Mylan, Inc., the Federal Circuit construed composition claims of two Angiomax patents as requiring the recited “batches” to be made by a specific “efficient mixing” process illustrated in one of the examples. While doing so may have preserved the validity of the patents, it required reversal of the district court’s … Continue reading this entry Tags: Angiomax,The Medicines Company
Friday the 13th may have been The Medicines Company’s lucky day, since the Federal Circuit granted its petition for rehearing en banc in The Medicines Company v. Hospira, Inc. In the court’s original decision, which I discussed in this article, the court found that the use of a contract manufacturer gave rise to an on … Continue reading this entry Tags: Hospira,On-Sale Bar,The Medicines Company
In The Medicines Company v. Hospira, Inc., the Federal Circuit held that a transaction with a contract manufacturer gave rise to an on sale bar that invalidated The Medicines Company’s Angiomax® patents. Are the facts of this case unusual, or does this decision put other pharmaceutical patents at risk? Would the on sale bar of … Continue reading this entry Tags: Hospira,On-Sale Bar,The Medicines Company
In a decision that sent The Medicines Company’s stock prices soaring, the District Court for the Eastern District of Virginia determined that the USPTO’s rejection of The Medicines Company’s application for Patent Term Extension was based on an incorrect—and unreasonable and unfair —interpretation of the governing statute. The patent at issue relates to Angiomax®, an … Continue reading this entry Tags: Angiomax,PTE,The Medicines Company
Posted in Claim Construction; Federal Circuit Decisions